Physician Information - Hand Procedure

Osteoarthritis is common in the carpometacarpal (CMC) joint of the thumb. On average, 10% of the population over 50, mostly women, is affected. Primary symptoms include pain, deformity, loss of mobility and weakness. In circumstances where appropriate conservative treatment has failed, surgery may be warranted.

Cartiva® Synthetic Cartilage Implant (SCI) for CMC is intended to treat diseased or damaged articular surfaces of the 1st carpometacarpal (CMC) joint associated with joint pain or decreased range of motion. The implant, a cylindrical device made from an elastic biomaterial, may be used as a replacement for damaged cartilage and bone without requiring the destruction or removal of a patient's healthy tissue. It is intended for use during a single surgical procedure. The procedure is similar to that used for osteochrondal autograft or allograft transplantation; a part is placed into a pre-drilled hole to resurface the damaged area of cartilage/bone.

Cartiva® SCI for CMC is made from a proprietary biomaterial. The device, which is classified as a hydrated polymer, consists of water in a similar proportion to human tissue. The organic polymer-based biomaterial is capable of withstanding repetitive loading typical of normal hand use, and its mechanical properties are similar to articular cartilage. Cartiva® SCI for CMC provides an alternative to tissue-based treatments without exposing the patient to the risk of viral transmission or an inflammatory response, because it does not contain substances derived from human or animal tissue.

The Cartiva® implant is intended to provide Surgeons with an alternative to total or partial trapeziectomy, arthroplasty or joint fusion. The Cartiva procedure preserves more bone, maintains motion in the joint, reduces rehabilitation time and enables patients to return to normal activity quickly. Also the procedure burns no bridges such that if revision is required, both trapeziectomy or ligament reconstruction tendon interposition are viable options.

Our unique cartilage replacement technology can revolutionize the way you approach OA of the 1st CMC joint, by offering your patients an alternative that:

  • Relieves pain
    The durable viscoelastic surface replacement mimics natural cartilage, providing flexible cushioning to maintain natural joint mechanics.
  • Maintains joint mobility
    By preserving the joint, patients may maintain the mobility desired for an active lifestyle.
  • Allows for quick recovery
    Implantation with Cartiva® SCI is a simple procedure. The patient benefits from a quick return to their normal activities.



Product Information

For more information see Cartiva® hand products
View products